Home › NDC Lookup › Ingredients › Allopurinol › 67046-0681-03
⚪image loading
(from DailyMed)

Allopurinol 300 mg Tablet, 30-count — NDC 67046-0681-3 (Billing 67046-0681-03)

by Coupler LLC · 30 TABLET in 1 BLISTER PACK

This is a package of 30 tablets of Allopurinol 300 mg Tablet from Coupler LLC, marketed since Feb 2018 and currently FDA-listed. It is this product's only package size.

NDC 67046-0681-03
🏷️ FDA NDC (as labeled) 67046-0681-3 billing pads the package segment with a zero
Rx only Generic On market Non-controlled ⇄ Compare with another NDC
🗂️ FDA directory synced Oct 1, 2026 · this listing last changed Jul 24, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

This page is curated, coded, and maintained by

Compiled from public FDA, CMS, DailyMed, NADAC, and related drug data sources. Editorial policy

NDC database record

One package, one record: these facts belong to NDC 67046-0681-3 alone.

Record
FDA NDC Directory package listing · Human prescription drug
Code segments
67046 labeler · 0681 product · 3 package
Package marketed since
Feb 23, 2018
Sample package
No — commercial package
Listing certified through
Dec 31, 2027
Barcode (UPC)
0303780181052
FDA record last changed
Jul 24, 2026

Identity & classification

Regulatory identifiers FDA, NLM and CMS codes for this package

FDA NDC (as labeled) 67046-0681-3
Product NDC 67046-0681
11-digit billing NDC 67046068103
RxCUI 197320
UNII 63CZ7GJN5I
UPC 0303780181052
Application # ANDA018659
SPL Set ID 65171cf0-8486-1ca6-e053-2991aa0ab91f
Established class (EPC) Xanthine Oxidase Inhibitor
Mechanism of action Xanthine Oxidase Inhibitors
DEA schedule Non-controlled
Marketing category ANDA
Marketing status On market
FDA listing status Listed (active directory)
Marketing start 2018-02-23
Route ORAL
Dosage form TABLET
Substance ALLOPURINOL
TE code (Orange Book) AB · RLD · RS
Quick answers
  • RxCUI (RxNorm): 197320
Why two NDCs? The FDA registers this code as 67046-0681-3 — a 5-4-1 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the package segment → 67046-0681-03. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

RxNorm drug class

This medicine belongs to the Xanthine Oxidase Inhibitor class.

Pharmacologic class Xanthine Oxidase Inhibitor
Drug family (ATC) Preparations inhibiting uric acid production
How it works Xanthine Oxidase Inhibitors
Where does this data come from?
Therapeutic classes from RxNorm RxClass (U.S. National Library of Medicine) — Established Pharmacologic Class (FDA), ATC drug family (WHO) and mechanism of action, matched by this product’s RxCUI.

Clinical

📗 Our plain-language guide HelloPharmacist
  • Allopurinol lowers uric acid. The tablets are used for gout, for high uric acid caused by cancer treatment, and for recurrent calcium oxalate kidney stones in certain adults. The I...
  • No. Flares can happen early as uric acid shifts, and it can take months to settle. Your doctor will likely suggest colchicine or an anti-inflammatory to help prevent them. Keep tak...
  • I got a gout flare after starting it. Should I stop?
  • Nausea, diarrhea and mild changes in liver tests are the most common. A skin rash is the one to take seriously. Stop the medicine and get medical help right away if a rash or aller...
📖 Read our full Allopurinol guide →
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer eachPer package
Retail pharmacies payNADAC · weekly Not in the retail survey — common for institutional, discontinued, or low-volume packs.
Medicaid paysCMS SDUD · 12 mo No recent Medicaid claims on file for this NDC — rare and low-volume NDCs are suppressed in the public data.
Medicare drug plans payPart D · Q2 2026 $0.1123 $3.37 / 30 tablets
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

Packaging — all sizes for this product

Package NDCDescription Marketing startMarketing endStatus
67046-0681-03 You're viewing this Main listing 30 TABLET in 1 BLISTER PACK 2018-02-23 — Active

Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
Allopurinol 300 mg 00378-0181-01 Mylan 100 tablets $0.052 AB Availability likely —
Allopurinol 300 mg 00591-5544-01 Actavis 100 tablets $0.052 — Availability likely —
Allopurinol 300 mg 00603-2116-21 Par 100 tablets $0.052 AB Availability likely —
Allopurinol 300 mg 00904-6572-61 Major 100 tablets $0.052 AB Availability likely —
Allopurinol 300 mg 16571-0885-09 Rising 90 tablets $0.052 AB Availability likely —
Allopurinol 300 mg 16714-0577-01 NorthStar 100 tablets $0.052 AB Availability likely —
Allopurinol 300 mg 23155-0694-01 Heritage 100 tablets $0.052 AB Discontinued —
Allopurinol 300 mg 29300-0350-01 Unichem 100 tablets $0.052 AB Availability likely —
Allopurinol 300 mg 31722-0253-01 Camber 100 tablets $0.052 AB Availability likely —
Allopurinol 300 mg 51079-0206-20 Mylan 100 tablets $0.052 AB Availability likely —
Allopurinol 300 mg 53489-0157-01 Sun 100 tablets $0.052 AB Availability likely —
Allopurinol 300 mg 55111-0730-01 Dr. 100 tablets $0.052 AB Availability likely —
Allopurinol 300 mg 59651-0286-01 Aurobindo 100 tablets $0.052 AB Availability likely —
Allopurinol 300 mg 60687-0688-01 American 100 tablets $0.052 AB Availability likely —
Allopurinol 300 mg 62135-0517-31 Chartwell 300 tablets $0.052 AB Availability likely —
Allopurinol 300 mg 69315-0292-01 Leading 100 tablets $0.052 AB Availability likely —
Allopurinol 300 mg 71921-0242-01 Florida 100 tablets $0.052 AB Availability likely —
Allopurinol 300 mg 16729-0135-01 Accord 100 tablets $0.075 AB FDA listed —
Allopurinol 300 mg 00615-8517-05 NCS 15 tablets — AB FDA listed —
Allopurinol 300 mg 14445-0171-00 Indoco 1000 tablets — AB FDA listed —
Allopurinol 300 mg 43063-0934-01 PD-Rx 100 tablets — AB FDA listed —
Allopurinol 300 mg 43063-0976-30 PD-Rx 30 tablets — AB FDA listed —
Allopurinol 300 mg 43353-0186-60 Aphena 90 tablets — AB FDA listed —
Allopurinol 300 mg 48433-0003-20 Safecor 100 tablets — AB FDA listed —
Allopurinol 300 mg 50090-4663-00 A-S 100 tablets — AB FDA listed —
Allopurinol 300 mg 50090-6882-00 A-S 100 tablets — AB FDA listed —
Allopurinol 300 mg 50090-6968-00 A-S 90 tablets — AB FDA listed —
Allopurinol 300 mg 50090-7351-00 A-S 100 tablets — AB FDA listed —
Allopurinol 300 mg 50090-7353-00 A-S 90 tablets — AB FDA listed —
Allopurinol 300 mg 50090-7792-00 A-S 100 tablets — AB FDA listed —
Allopurinol 300 mg 51655-0782-26 Northwind 90 tablets — AB FDA listed —
Allopurinol 300 mg 51655-0968-26 Northwind 90 tablets — AB FDA listed —
Allopurinol 300 mg 55154-5454-00 Cardinal 10 tablets — AB FDA listed —
Allopurinol 300 mg 55154-7981-00 Cardinal 10 tablets — AB FDA listed —
Allopurinol 300 mg 60760-0722-90 ST. 90 tablets — AB FDA listed —
Allopurinol 300 mg 60760-0989-90 St. 90 tablets — AB FDA listed —
Allopurinol 300 mg 63187-0240-30 Proficient 30 tablets — AB FDA listed —
Allopurinol 300 mg 63629-1781-01 Bryant 30 tablets — AB FDA listed —
Allopurinol 300 mg 63629-2112-01 Bryant 500 tablets — AB FDA listed —
Allopurinol 300 mg 63629-2113-01 Bryant 1000 tablets — AB FDA listed —
Allopurinol 300 mgthis 67046-0681-03 Coupler 30 tablets — AB FDA listed —
Allopurinol 300 mg 67046-1514-03 Coupler 30 tablets — AB FDA listed —
Allopurinol 300 mg 67046-1639-03 Coupler 30 tablets — AB FDA listed —
Allopurinol 300 mg 67046-1658-03 Coupler 30 tablets — AB FDA listed —
Allopurinol 300 mg 67544-0313-45 Aphena 45 tablets — AB FDA listed —
Allopurinol 300 mg 68071-3605-09 NuCare 90 tablets — AB FDA listed —
Allopurinol 300 mg 68071-3672-09 NuCare 90 tablets — AB FDA listed —
Allopurinol 300 mg 68788-6323-01 Preferred 100 tablets — AB FDA listed —
Allopurinol 300 mg 68788-8364-01 Preferred 100 tablets — AB FDA listed —
Allopurinol 300 mg 68788-8424-01 Preferred 100 tablets — AB FDA listed —
Allopurinol 300 mg 68788-8713-01 Preferred 100 tablets — AB FDA listed —
Allopurinol 300 mg 68788-8865-01 Preferred 100 tablets — AB FDA listed —
Allopurinol 300 mg 70518-3704-00 REMEDYREPACK 30 tablets — AB FDA listed —
Allopurinol 300 mg 70518-4286-00 REMEDYREPACK 30 tablets — AB FDA listed —
Allopurinol 300 mg 70518-4404-00 REMEDYREPACK 30 tablets — AB FDA listed —
Allopurinol 300 mg 70518-4556-00 REMEDYREPACK 100 tablets — AB FDA listed —
Allopurinol 300 mg 70710-1210-00 Zydus 1000 tablets — AB FDA listed —
Allopurinol 300 mg 70771-1127-00 Zydus 1000 tablets — AB FDA listed —
Allopurinol 300 mg 71205-0049-30 Proficient 30 tablets — AB FDA listed —
Allopurinol 300 mg 71205-0377-30 Proficient 30 tablets — AB FDA listed —
Allopurinol 300 mg 71335-0112-01 Bryant 30 tablets — AB FDA listed —
Allopurinol 300 mg 71335-2332-01 Bryant 30 tablets — AB FDA listed —
Allopurinol 300 mg 71335-3082-01 Bryant 30 tablets — AB FDA listed —
Allopurinol 300 mg 71335-9634-01 Bryant 30 tablets — AB FDA listed —
Allopurinol 300 mg 71335-9676-01 Bryant 30 tablets — AB FDA listed —
Allopurinol 300 mg 71610-0064-45 Aphena 45 tablets — AB FDA listed —
Allopurinol 300 mg 71610-0253-60 Aphena 90 tablets — AB FDA listed —
Allopurinol 300 mg 71610-0681-45 Aphena 45 tablets — AB FDA listed —
Allopurinol 300 mg 72162-1150-00 Bryant 1000 tablets — AB FDA listed —
Allopurinol 300 mg 72189-0417-90 Direct_Rx 90 tablets — AB FDA listed —
Allopurinol 300 mg 72189-0647-90 Direct_Rx 90 tablets — AB FDA listed —
Allopurinol 300 mg 72865-0304-01 XLCare 100 tablets — AB FDA listed —
Allopurinol 300 mg 80425-0206-01 Advanced 30 tablets — AB FDA listed —
Allopurinol 300 mg 80425-0383-01 Advanced 30 tablets — AB FDA listed —
Allopurinol 300 mg 80425-0518-01 Advanced 30 tablets — AB FDA listed —
Allopurinol 300 mg 82638-0113-02 Harman 100 tablets — AB FDA listed —
Allopurinol 300 mg 82868-0099-30 Northwind 30 tablets — AB FDA listed —
Allopurinol 300 mg 70518-4693-00 REMEDYREPACK 100 tablets — AB FDA listed —
Allopurinol 300 mg 71335-3154-01 Bryant 30 tablets — AB FDA listed —
Allopurinol 300 mg 55154-0282-00 Cardinal 10 tablets — AB FDA listed —
Allopurinol 300 mg 53401-0025-60 Aphena 90 tablets — AB FDA listed —
Allopurinol 300 mg 72789-0593-90 PD-Rx 90 tablets — AB FDA listed —
About this product: this is a generic version of the medicine. FDA equivalence ratings are shown when available, and other versions are listed above, least expensive first.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

Availability & generic status

🏛️
2018
On the market since
Feb 2018
📍
2026
Currently FDA-listed
8 years listed
🔓
·
Generic on the market
this product is a generic
✅This is a generic drug

This product is an FDA-approved generic. Other versions of the same drug are listed under Therapeutic equivalents, least expensive first.

Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

What it looks like

Color white
ShapeRound
ImprintM;71
Size11 mm
ScoringScored — splits in 2
One label can cover several strengths, so colors may be combined — always confirm a loose pill against the dispensed prescription label or a pharmacist.
Where does this data come from?
Physical description (imprint, shape, color, scoring, coating) from this product’s FDA Structured Product Labeling (SPL), mirrored from DailyMed / openFDA.

Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

Loading inactive ingredients from the official FDA label in the background. No external source is being called by this page request.
Where does this data come from?
Source: official FDA Structured Product Labeling (SPL) via DailyMed and the openFDA label index. Structured IACT rows and label-wide narrative are kept separate; availability and product-level specificity depend on the submitted label.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

Manufacturer & labeler

LabelerCoupler LLC
Application holderMYLAN PHARMACEUTICALS INC
FDA applicationANDA018659 (ANDA)
Labeler code67046
First marketedFeb 2018
Product typeHuman Prescription Drug
Portfolio465 products on file

More NDCs from Coupler LLC labeler code 67046

The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

Full prescribing information FDA SPL

The complete FDA label for this product — the official prescribing information, verbatim, section by section. Jump with a chip, search within the label, or expand everything.
💬 Patient Medication Information
💬 Patient Medication Information ~3 min read ▾

Mylan Pharmaceuticals Inc. Allopurinol allopurinol ALLOPURINOL ALLOPURINOL SILICON DIOXIDE MAGNESIUM STEARATE CELLULOSE, MICROCRYSTALLINE STARCH, CORN SODIUM LAURYL SULFATE SODIUM STARCH GLYCOLATE TYPE A POTATO M;31 Allopurinol allopurinol ALLOPURINOL ALLOPURINOL SILICON DIOXIDE MAGNESIUM STEARATE CELLULOSE, MICROCRYSTALLINE STARCH, CORN SODIUM LAURYL SULFATE SODIUM STARCH GLYCOLATE TYPE A POTATO M;71 DESCRIPTION Allopurinol has the following structural formula: Allopurinol is known chemically as 1,5-dihydro-4H-pyrazolo [3,4-d] pyrimidin-4-one.

It is a xanthine oxidase inhibitor which is administered orally. Its solubility in water at 37°C is 80.0 mg/dL and is greater in an alkaline solution. Each tablet for oral administration contains either 100 mg or 300 mg of allopurinol, USP and the following inactive ingredients: colloidal silicon dioxide, magnesium stearate, microcrystalline cellulose, pregelatinized starch, sodium lauryl sulfate and sodium starch glycolate.

Allopurinol Structural Formula CLINICAL PHARMACOLOGY Allopurinol acts on purine catabolism, without disrupting the biosynthesis of purines. It reduces the production of uric acid by inhibiting the biochemical reactions immediately preceding its formation. Allopurinol is a structural analogue of the natural purine base, hypoxanthine.

It is an inhibitor of xanthine oxidase, the enzyme responsible for the conversion of hypoxanthine to xanthine and of xanthine to uric acid, the end product of purine metabolism in man. Allopurinol is metabolized to the corresponding xanthine analogue, oxipurinol (alloxanthine), which also is an inhibitor of xanthine oxidase. It has been shown that reutilization of both hypoxanthine and xanthine for nucleotide and nucleic acid synthesis is markedly enhanced when their oxidations are inhibited by allopurinol and oxipurinol.

This reutilization does not disrupt normal nucleic acid anabolism, however, because feedback inhibition is an integral part of purine biosynthesis. As a result of xanthine oxidase inhibition, the serum concentration of hypoxanthine plus xanthine in patients receiving allopurinol for treatment of hyperuricemia is usually in the range of 0.3 mg to 0.4 mg/dL compared to a normal level of approximately 0.15 mg/dL. A maximum of 0.9 mg/dL of these oxypurines has been reported when the serum urate was lowered to less than 2 mg/dL by high doses of allopurinol.

These values are far below the saturation levels at which point their precipitation would be expected to occur (above 7 mg/dL). The renal clearance of hypoxanthine and xanthine is at least 10 times greater than that of uric acid. The increased xanthine and hypoxanthine in the urine have not been accompanied by problems of nephrolithiasis.

Xanthine crystalluria has been reported in only three patients. Two of the patients had Lesch-Nyhan syndrome, which is characterized by excessive uric acid production combined with a deficiency of the enzyme, hypoxanthine guanine phosphoribosyltransferase (HGPRTase). This enzyme is required for the conversion of hypoxanthine, xanthine, and guanine to their respective nucleotides.

The third patient had lymphosarcoma and produced an extremely large amount of uric acid because of rapid cell lysis during chemotherapy. Allopurinol is approximately 90% absorbed from the gastrointestinal tract. Peak plasma levels generally occur at 1.5 hours and 4.5 hours for allopurinol and oxipurinol, respectively, after a single oral dose of 300 mg allopurinol, maximum plasma levels of about 3 mcg/mL of allopurinol and 6.5 mcg/mL of oxipurinol are produced.

Approximately 20% of ingested allopurinol is excreted in the feces. Because of its rapid oxidation to oxipurinol and a renal clearance rate approximately that of glomerular filtration rate, allopurinol has a plasma half-life of about 1 to 2 hours. Oxipurinol, however, has a longer plasma half-life (approximately 15 hours) and therefore effective xanthine oxidase inhibition is maintained over a 24 hour per…

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗

Medicare Part D spend CMS · PART D · 2026 (Q1)

Medicare Part D (outpatient prescription) spending for Allopurinol — the program that covers self-administered drugs. 19 manufacturers.
⚠️ Drug-level data: CMS publishes Part D spending by drug, not by NDC — these figures combine every manufacturer, strength and package size sold under the name Allopurinol. That’s a different level of aggregation than the Medicaid card above, which is specific to this exact 11-digit NDC (pack size included), so the two aren’t directly comparable.
Period
Total Part D spend
$25.19M
Claims incl. refills
2.4M
Beneficiaries
1.9M
Spend / beneficiary
$13.47
Spend / claim
$10.36
Trend by period
💵 About the dollar figures: spending is what Part D plans paid before confidential manufacturer rebates, so the program’s real net cost is lower. A blank patient count means fewer than 11 people — CMS hides counts that small to protect privacy. Source: CMS Medicare Quarterly Part D Spending by Drug (data.cms.gov), updated quarterly.

About this NDC listing & data coverage

Finished prescription product
What data is (and isn’t) available for this NDC — tap to expand
NDC identity (package / product / labeler codes) ✓ Available
Labeler ✓ Available
Product & package description ✓ Available
Marketing category & status ✓ Available
Active ingredient / dosage form / route ✓ Available
FDA label (SPL via DailyMed) ✓ Available
Package photos — Not published for this NDC No photo available yet for this listing.
Inactive ingredients (structured) — Not published for this NDC The labeler did not submit a structured excipient list, or no SPL is available.
NADAC pharmacy acquisition price (CMS) — Not published for this NDC CMS publishes NADAC only for NDCs reported in its retail-pharmacy survey.
Orange Book / therapeutic-equivalence data ✓ Available
HCPCS J-code billing crosswalk — Not published for this NDC Most self-administered / retail products have no J-code — that is normal.
Medicaid utilization (CMS SDUD) — Not published for this NDC CMS reports utilization only for NDCs with Medicaid claims above its privacy threshold.
“Not published” reflects what the public FDA / CMS / NLM sources provide for this exact package code — it is a property of the data feeds, not a judgment about the product.

Questions about this listing

Why is there no price listed?
The pricing shown on our NDC pages comes from CMS NADAC, a voluntary survey of retail community pharmacy invoices. CMS does not publish a NADAC for every NDC — packages outside the retail survey (institutional and hospital products, bulk packages, discontinued items, and many OTC items) may never receive one. A missing price reflects the survey's scope, not this product's actual cost, and does not mean the product is free or unavailable.
Is the NDC printed on the package the same as the 11-digit billing NDC?
Yes, they identify this exact package in different formats. The form printed on the packaging and shown on DailyMed is the one the FDA registered. Insurance claims use a fixed 11-digit 5-4-2 format, so the short segment is padded with a leading zero and the dashes are dropped. The Identity section at the top of this page lists each form of this code.
Is this package still being marketed?
Yes, per the latest FDA NDC Directory data on this page: this package is listed as actively marketed, with no marketing end date reported by Coupler LLC. Listing status can change — the directory data on this page refreshes weekly.
Who lists this product with the FDA?
Coupler LLC is the labeler of record for this NDC — the company under whose FDA-assigned code the package is listed. The labeler may be the manufacturer itself or a distributor marketing the product under its own code.
Do I need a prescription for this product?
This NDC is listed with FDA as a prescription product, so it is dispensed under a prescriber's order. Your pharmacist can tell you whether any over-the-counter forms of the same medication exist.
This page identifies an FDA-listed package (the NDC) and reports public regulatory and pricing data about the listing. It is reference information, not a medical recommendation — talk to your pharmacist or prescriber about your own medication.
Where does this data come from?
Listing facts (marketing category, packager status, marketing dates) from the FDA openFDA NDC Directory; label availability from DailyMed; pricing coverage from CMS NADAC; equivalence scope from the FDA Orange Book.
← 67046-0680-03 · Coupler 67046-0689-03 · Coupler →
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.